Interestingly, venetoclax is especially potent in AML cells with isocitrate dehydrogenase 1 and 2 (IDH1/2) gene mutations; these proteins have been implicated in increasing BCL-2 dependence86. This evidence concerns the gene IDH1 and acute myeloid leukemia.